CRISPR-edited tumor-infiltrating lymphocytes are emerging as a promising alternative to CAR T-cell therapy for solid cancers.

IgA nephropathy is a rare condition caused by excessive buildup of immunoglobulin A in the kidneys, slowly but progressively ...

IRVINE, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today reported its first quarter 2026 operating and financial results and provided recent ...

Probability of Remaining Event-Free at Three Years by Kaplan-Meier Analysis After Achieving Complete Response at Three MonthsFirst and Only ...

Taiho Oncology, Inc. and Taiho Pharmaceutical Co., Ltd., today announced that the U.S. Food and Drug Administration (FDA) has approved INQOVI (decitabine and cedazuridine) plus venetoclax as a ...

Using the BLISS-LN phase 3 study of belimumab, investigators studied biomarker associations with kidney response in lupus nephritis.

Merck highlights new long-term data and advancements across broad oncology portfolio and pipeline research at ASCO 2026: Rahway, New Jersey Wednesday, May 13, 2026, 11:00 Hrs [IST ...

Detailed price information for Palisade Bio Inc (PALI-Q) from The Globe and Mail including charting and trades.

Background Cardiovascular disease and osteoarthritis (OA) share risk factors, but the link between comprehensive ...

BEQALZI™ (sonrotoclax) is a BCL-2 inhibitor indicated for the treatment of adult patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL) after at least two lines of systemic therapy, ...

China: Levofloxacin demonstrated good clinical effectiveness in children with refractory Mycoplasma pneumoniae pneumonia ...

Objective B-cell activating factor (BAFF) is essential for B-cell survival and innate immune activation, and its ...